Fig. 3.

Gene expression analysis of selected genes involved in the activity of oxaliplatin and pemetrexed. a modulation of ERCC1 and ERCC2 mRNA expression by pemetrexed, at IC₅₀ levels. b Modulation of ERCC1 and ERCC2 mRNA expression by 5-fluorouracil (5-FU), methotrexate, LY309887, at IC₅₀ levels, in HT29 cells. c FPGS, TS, DHFR and GARFT mRNA modulation after oxaliplatin exposure at IC₅₀ levels. Data represent mean values ±SD from three independent experiments*P < 0.05, **P < 0.01, ***P < 0.001 with respect to control. In particular, the results of the repeated measures ANOVA followed by the Tukey’s test were 0.001, 0.007, 0.033 and 0.045 for the modulation of ERCC1 and ERCC2 after pemetrexed exposure in the HT29, WiDR, SW620 and LS174T cells, respectively; 0.023 for the modulation of ERCC1 and ERCC2 after 5-FU exposure in the HT29 cells; and 0.023, 0.003 and <0.001 for the modulation of FPGS, TS, DHFR and GARFT after oxaliplatin exposure, in the WiDr, SW620 and LS1574T cells, respectively